Next generation deep sequencing identified a novel lncRNA n375709 associated with paclitaxel resistance in nasopharyngeal carcinoma

Abstract

Paclitaxel chemoresistance restricts the therapeutic efficacy and prognosis of patients with nasopharyngeal carcinoma (NPC). Accumulating evidence suggests that aberrant expression of long non-coding RNAs (lncRNAs) contributes to cancer progression. Therefore, we aimed to identify lncRNAs associated with paclitaxel resistance in NPC. First, paclitaxel-resistant CNE-2 cells (CNE-2-Pr) were successfully established and confirmed to be 33.26±8.70 times more resistant than parental CNE-2 cells. Then, differential expression profile of lncRNAs associated with NPC paclitaxel resistance, which contained a total of 2,670 known lncRNAs and 4,820 novel lncRNAs, was constructed via next generation sequencing technology. Our qRT-PCR confirmed that 7 of the top 8 lncRNAs were expressed with the same trend as the prediction, including 4 known lncRNAs (n375709, n377806, n369241 and n335785) and 3 novel lncRNAs (Unigene6646, Unigene6644 and Unigene1654). Our group initially focused on lncRNA n375709, which was the most significantly overexpressed lncRNA of the known lncRNAs. CCK-8 assays demonstrated that further inhibition of lncRNA n375709 increased the paclitaxel sensitivity in NPC 5-8F and 6-10B cells. In conclusion, the present study provided an overview of the expression profiles of lncRNAs correlated with paclitaxel resistance. lncRNA n375709 was identified to be involved in the regulation of NPC paclitaxel resistance.

LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting Rsf-1 and modulating the Ras-MAPK pathway

“…23 Additionally, n375709, a newly identified lncRNA, was documented to be highly expressed in NPC cells and implicated in the regulation of NPC paclitaxel resistance. 24 However, the roles of NEAT1 and its underlying mechanisms in cisplatin resistance remain unclear. In our study, we confirmed the upregulation of NEAT1 in NPC tissues and cells.…”

<p>Novel Tumor Suppressor lncRNA Growth Arrest-Specific 5 (GAS5) In Human Cancer</p>

“…In recent years, GAS5 has raised increased attention due to its downregulation in a wide variety of malignancies, including non-small cell lung cancer (NSCLC), 16,17 breast cancer (BC), 18,19 hepatocellular carcinoma (HCC), 20,21 esophageal carcinoma (EC), 22,23 gastric cancer (GC), 24,25 colorectal cancer (CRC), 26,27 pancreatic cancer (PC), 28,29 cervical cancer (CC), 30,31 ovarian cancer (OC), 32,33 renal cell carcinoma (RCC) 34,35 (Figure 1). Clinicopathological characteristics, such as overall survival (OS), disease-free survival (DFS), distant metastasis (DM), lymph node metastasis (LNM), tumor node stage (TNM) and tumor size, are highly correlated with the level of GAS5 expression in cancers, 16,19,27,36,37 indicating that GAS5 can be a novel diagnostic and prognostic biomarker, as well as therapeutic target in many human cancers.…”

Downregulation of lncRNA ANRIL inhibits proliferation, induces apoptosis, and enhances radiosensitivity in nasopharyngeal carcinoma cells through regulating miR-125a

“…8,9 Recently, Ren et al identified a novel lncRNA n375709 by next generation deep sequencing, which was overexpressed and led to paclitaxel resistance in NPC. 10 LncRNA ANRIL (CDKN2B antisense RNA 1) was located a 42-kb stretch on the chromosome 9p21, which was originally identified from familial melanoma patients with germline deletion in the INK4B-ARFINK4A gene cluster. 11,12 Subsequently, accumulating documents have indicated that ANRIL is deregulated in various malignancies, such as lung cancer, breast cancer, gastric cancer.…”